ADJUVANT COMPARISON AND CHARACTERIZATION

佐剂比较和表征

• 批准号: 10703849
• 负责人: BALI PULENDRAN
• 金额: $ 329.97万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10703849
• 关键词: Adjuvant; COVID-19 vaccine; Data Analyses; Fingerprint; Goals; Human; Immune; Immunologics; Mus; Organoids; Side; Tissues; Tonsil; Vaccine Antigen; Work; adaptive immune response; clinically relevant; data management; programs

The goal of the Adjuvant Comparison and Characterization (ACC) program is to support side-by-side comparison of adjuvants in combination with clinically relevant vaccine/antigen platforms, and to establish both systemic and tissue-specific immunological profiles (“immune fingerprints”) of adjuvants that work through different mechanisms in the context of Sars-CoV-2 vaccines.

佐剂比较和表征 (ACC) 计划的目标是支持佐剂与临床相关疫苗/抗原平台相结合的并列比较，并建立佐剂的系统和组织特异性免疫学特征（“免疫指纹”），这些佐剂在 Sars-CoV-2 疫苗的背景下通过不同机制发挥作用。